Wells Fargo
INDV icon

Wells Fargo’s Indivior Pharmaceuticals INDV Stock Holding History

Wells Fargo’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.86M Sell
290,839
-35,134
-11% -$1.16M ﹤0.01% 2141
2025
Q4 		$11.7M Buy
325,973
+247,516
+315% +$7.56M ﹤0.01% 1907
2025
Q3 		$1.89M Buy
78,457
+11,163
+17% +$234K ﹤0.01% 3345
2025
Q2 		$992K Buy
67,294
+66,118
+5,622% +$770K ﹤0.01% 3691
2025
Q1 		$11K Sell
1,176
-387
-25% -$4.07K ﹤0.01% 5864
2024
Q4 		$20K Buy
1,563
+296
+23% +$3.04K ﹤0.01% 5768
2024
Q3 		$12.5K Buy
1,267
+176
+16% +$2.06K ﹤0.01% 5740
2024
Q2 		$17.1K Sell
1,091
-329
-23% -$5.94K ﹤0.01% 5622
2024
Q1 		$30.4K Sell
1,420
-2
-0.1% -$38 ﹤0.01% 5446
2023
Q4 		$21.5K Sell
1,422
-4
-0.3% -$71 ﹤0.01% 5620
2023
Q3 		$31K Sell
1,426
-40
-3% -$912 ﹤0.01% 5419
2023
Q2 		$33.9K Buy
+1,466
New +$33.6K ﹤0.01% 5579

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wells Fargo's INDV Position: Q1 2026 in Review

Wells Fargo reduced its Indivior Pharmaceuticals (INDV) stake by 11% in Q1 2026, selling an estimated $1.16M and leaving 290,839 shares worth $8.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2141.

Wells Fargo first reported a position in INDV in Q2 2023 and has held it in 12 quarters since. The position peaked at $11.7M in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Wells Fargo held 290,839 shares of Indivior Pharmaceuticals worth $8.86M as of Q1 2026.
  • Wells Fargo sold 35,134 Indivior Pharmaceuticals shares in Q1 2026, an estimated $1.16M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2141 holding.
  • Wells Fargo first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Wells Fargo's Indivior Pharmaceuticals position peaked at $11.7M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.